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Falls are a major source of disability in Parkinson’s disease. Risk factors for falling in Parkinson’s disease remain unclear. To
determine the relevant risk factors for falling in Parkinson’s disease, we screened 160 consecutive patients with Parkinson’s disease
for falls and assessed 40 variables. A comparison between fallers and nonfallers was performed using statistical univariate analyses,
followed by bivariate and multivariate logistic regression, receiver-operating characteristics analysis, and Kaplan-Meier curves.
38.8% of patients experienced falls since the onset of Parkinson’s disease (recurrent in 67%). Tinetti Balance score and Hoehn and
Yahr staging were the best independent variables associated with falls. The Tinetti Balance test predicted falls with 71% sensitivity
and 79% speciﬁcity and Hoehn and Yahr staging with 77% sensitivity and 71% speciﬁcity. The risk of falls increased exponentially
with age, especially from 70 years onward. Patients aged >70 years at the onset of Parkinson’s disease experienced falls signiﬁcantly
earlier than younger patients.
1.Introduction
Falls are a major source of morbidity and disability in
Parkinson’s disease (PD). The risk of falls is increased in
patients with PD [1], and the ﬁndings of several studies have
revealedthat38to87%ofparkinsonian patients experienced
falls [2–5]. Falls are commonly a recurrent phenomenon in
PD. One meta-analysis of several prospective studies showed
that the rate of recurrent falling over a three-month period
was 57% among those patients who had reported previous
falls [6].
Direct consequences of falling are fractures, particularly
hip fractures, head trauma, contusions and other injuries
[5, 7–9], and even death [10]. In addition, falling may induce
fear of new falls [11], which can in turn reduce mobility and
lead to osteoporosis, loss of independence, social isolation,
and depression [12]. Moreover, falls increase the risk of
admission of PD patients to hospitals [13] and nursing
homes [5]. The economic burden of falls in PD is very high
and it is estimated that the direct medical costs of PD fallers
double those of nonfallers [14].
Preventing falls has become one of the most important
unmet needs in PD, and potential strategies to prevent falls
should focus on patients at higher risk for falling. Therefore,
identifying risk factors is of paramount importance.
Studies aimed at ﬁnding such risk factors have been
inconclusive to date. Retrospective studies have brought out
inconsistent results. Thus, falls in PD have been related
to age [15], disease duration [16, 17], disease severity [3,
17], autonomic dysfunction [15], urinary incontinence [4],
increased time in the get-up-and-go test [4], greater postural
sway [18, 19], poorer stability in response to pushes and
pulls[20],andvariabilityofstridetime[17].Otherproposed
predictors of falls include poor standing balance [21, 22],
dyskinesia, dementia, frontal impairment, freezing of gait
[23], orthostatic hypotension, and muscle weakness [24].
The best predictor of falling in PD found in a meta-
analysis of prospective studies with follow-up periods of2 Parkinson’s Disease
three months [2, 3], six months [25], and twelve months
[26]w a ss u ﬀering two or more falls in the previous year [6].
Although this conclusion reinforces the concept of recurrent
falls in PD, it does not help to identify PD patients at risk
before the ﬁrst fall. A more recent prospective study with a
six-month follow-up in patients with early-stage PD failed
to identify risk factors for the ﬁrst fall apart from increased
postural sway when standing on a ﬁrm and foam surface
with the eyes open in the group of fallers [27]. The follow-up
period of these studies might have been insuﬃcient to assess
theprospectivepredictivenessofagingordiseaseprogression
ontheappearanceoffalls,ifthesevariableswererelevantrisk
factors for falling in PD.
To try to elucidate the relevant risk factors for falling
in PD, we carried out a cross-sectional study of a group of
unselected patients of diﬀerent ages and disease duration,
taking into account most of the clinical variables potentially
associated with falls.
2. Methods
2.1. Subjects. The study sample comprised consecutive pa-
tients with PD who attended the Movement Disorders Clinic
of Hospital Universitario Gregorio Mara˜ n´ on during a nine-
month period. These patients were regularly followed up
with visits to the clinic every 3-4 months. The diagnosis
of PD was conﬁrmed according to the United Kingdom
Parkinson’s Disease Brain Bank criteria [28]. Patients who
underwent functional stereotactic surgery for PD were
excluded. The local ethics committee approved the study and
allparticipantsgavetheirinformedconsent.Allpatientswere
interviewed and examined by the authors.
2.2. Assessment of Falls. A fall was deﬁned as an event which
resulted in the patient unintentionally coming to the ground
or other lower level not as a result of a major intrinsic
event or overwhelming hazard [29, 30]. The patients were
questionedabouttheexistenceoftheseeventssincetheonset
of PD. Information about the time of the ﬁrst fall (year,
month) was obtained from the patients and checked with
relatives, caregivers, and clinical records for accuracy of data.
In cases with more than one fall, the number of falls in the
last year, and particularly in the last day, week, month, three-
month period, and six-month period, was recorded. Fall-
related injuries, especially fractures, were also recorded.
2.3. Variables. We recorded gender, age, age at onset of PD,
initial predominant symptom (tremor or akinetic-rigid syn-
drome), disease duration, and the presence of motor ﬂuctu-
ations and dyskinesia.
We also recorded treatments with antiparkinsonian
drugs including L-dopa (L-dopa/carbidopa, L-dopa/benser-
azide, controlled-release L-dopa formulations), COMT in-
hibitors (entacapone, tolcapone), MAO-B inhibitors (selegi-
line, rasagiline), amantadine, anticholinergics, and dopam-
ine agonists (bromocriptine, pergolide, cabergoline, prami-
pexole, ropinirole, transdermal rotigotine, subcutaneous
apomorphine) until the date of the survey (nonfallers) or
the date of the ﬁrst fall. Only sustained treatment for more
than two months at recommended doses was considered.
Treatment with benzodiazepines, antidepressants, atypical
neuroleptics (quetiapine, clozapine), and cholinesterase in-
hibitors was also recorded in the same manner.
History of syncope and symptoms of orthostatic hypot-
ension (light-headedness, dizziness, weakness on standing
from sitting or lying position) [31] were recorded as were
past history of stroke, hypertension, and diabetes.
Clinical data were obtained from the patients and
checked with relatives, caregivers, and clinical records for
accuracy.
All patients underwent neuroimaging studies (cranial-
computed tomography, brain magnetic resonance imaging
[MRI], or both), which were reviewed by a neuroradiologist
to identify cases with moderate/severe leukoaraiosis and
infarcts of any size and location. All PD fallers underwent
brain MRI after the onset of falls.
The motor function subscale (part III) of the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS) [32] was admin-
istered, as were the Schwab and England activities of daily
living [33], Hoehn and Yahr staging [34], Mini Mental State
Examination [35], Tinetti’s Gait and Balance functional test
[36] (the appendix), and the freezing of gait questionnaire
[37].
The timed get-up-and-go test [38]w a sp e r f o r m e da n da
ten-meter walk at the preferred speed was timed, videotaped,
and used to calculate gait velocity, and step length and
cadence.
In ﬂuctuating patients, UPDRS, Schawb-England, and
Hoehn and Yahr scales and timed tests were administered
in oﬀ situation (8–10 hours after patients stopped their
usual antiparkinsonian treatment) to evaluate the possible
inﬂuence of disease severity.
2.4. Statistical Analysis. Mean diﬀerences between fallers
and nonfallers were assessed using the t-test for indepen-
dent samples or the Mann-Withney U test for continuous
variables with parametric or nonparametric distribution,
respectively. The χ2 test was used to assess associations
between categorical variables.
Variables with statistically signiﬁcant diﬀerences between
fallers and nonfallers were entered into bivariate and
stepwise multivariate logistic regression analyses with the
dichotomous criterion of falls as the common regressor
to determine the best explanatory independent variables.
Several stepwise multivariate logistic regression models were
tested, evaluating all possible combinations of the variables.
Up to ﬁve variables were considered in each model.
Receiver operating characteristic (ROC) analyses were
performed to assess the sensitivity and speciﬁcity of each
variable in predicting fallers. The point that simultaneously
maximized sensitivity and speciﬁcity was selected as the cut-
oﬀ value. Accuracy was calculated based on the proportion
of correctly classiﬁed cases using cut-oﬀ values.
Kaplan-Meier curves were used to evaluate the relation-
ship between time to onset of falls and age and disease
duration. The log-rank test stratiﬁed by age at onset of PDParkinson’s Disease 3
was performed to evaluate the eﬀect of age at onset on the
appearanceoffallsduringthecourseofthedisease.A P value
< 0.05 was considered signiﬁcant in all tests.
Data were analysed using the Statistical Package for the
Social Sciences (SPSS) version 15.0 for Windows.
3. Results
The study sample comprised 160 patients with PD (72 men,
88 women, mean age 72 ± 9.5y e a r s ) .D e m o g r a p h i ca n d
disease characteristics are described in Table 1. Sixty-two
patients (38.8%) reported at least one fall since the onset
of PD, and 42 of these patients were recurrent fallers (68%
of patients with falls). The average frequency of falls in the
previous year in recurrent fallers was as follows: one or more
falls per day, 4.8%; one fall per week, 9.7%; one fall per
month, 25.8%; one fall every six months, 59.7%.
Falls led to fractures in 20 patients (32.2% of fallers) and
to bruises, skin lacerations, and other injuries in a further 16
cases (25.8% of fallers).
At the ﬁrst fall, mean age was 70.7 ± 9.6 years and the
mean disease duration when the ﬁrst fall occurred was 7.2 ±
6y e a r s .
Thirty-two patients were unable to perform timed tests
becausetheycouldnotwalkunaided(HoehnandYahrstages
IV and V).
3.1. Comparison between Fallers and Nonfallers. Fallers were
older and had longer disease duration and increased dis-
ease severity according to the UPDRS (part III), Hoehn
and Yahr and Schwab and England activities of daily living
scores. In addition, fallers scored worse in the Mini-Mental
State Examination and experienced a higher frequency
of motor ﬂuctuations, dyskinesia, and freezing of gait
(Table 1). Tremor as the initial predominant symptom was
more frequent in nonfallers. Fallers were treated with higher
doses of levodopa and more frequently received COMT
inhibitors, central cholinesterase inhibitors, and atypical
neuroleptics (quetiapine) than nonfallers (Table 2). Patients
treated with central cholinesterase inhibitors (rivastigmine)
had dementia associated with PD and those treated with
quetiapine had hallucinations.
No diﬀerenceswereobservedbetweenfallersandnonfall-
ers in other drug treatments, age at onset of PD, symptoms
of orthostatic hypotension and cerebrovascular disease (clin-
ical, neuroimaging, and risk factors).
Fallers scored worse in the Balance and Gait subscales
of the Tinetti functional test and were slower in the timed
get-up-and-go test (Table 2). There were no statistically sig-
niﬁcant diﬀerences in gait velocity, step length, and cadence
between fallers and nonfallers.
3.2. Regression Analysis. The independent variables identi-
ﬁed as signiﬁcantly associated with falls in the bivariate
logistic regression were the same as those that had been
found to be statistically diﬀerent in the previous approach,
except for the timed get-up-and-go test, which lost its
statistical signiﬁcance (Table 3).
When these variables were included in stepwise multi-
variate models of logistic regression, only the Tinetti Balance
functionaltestwasindependentlyassociatedwithfalls(OR =
0.847, 95% CI = 0.740–0.971, P = 0.017). The rest of the
variables lost their statistical signiﬁcance once Tinetti Bal-
ance subscale entered into the regression model. In Table 3
appear the most favorable OR obtained for the other vari-
ables, which did not reach in any case the threshold of
statistical signiﬁcance.
3.3. ROC Analysis. Table 4 shows the outcomes of the ROC
analysis for the nondichotomous variables associated with
falls in the bivariate logistic regression. Again the Tinetti
Balance functional test showed the highest combination of
sensitivityandspeciﬁcity(71%and79%resp.) forpredicting
falls followed by Hoehn and Yahr staging (77% and 71%),
with an accuracy of 76% and 74%, respectively, (Figures 1(a)
and 1(b)). The combination of these two variables increased
speciﬁcity to 80% and accuracy to 77%. Seventy-seven per
cent of fallers were in Hoehn and Yahr stage ≥3 whereas 72%
of nonfallers were in stages 1 and 2 (Table 1).
3.4. Kaplan-Meier Curves. Survival curves show that the risk
of falls increased exponentially with age, particularly from
the age of 70 years (Figure 2). In addition, the prevalence
of falls increased with the duration of PD (Figure 3). The
combined eﬀect of age at onset of PD and disease duration
is illustrated in Figure 4. Patients who developed PD after
the age of 70 years experienced falls signiﬁcantly earlier than
younger patients (log rank, P<0.001).
4. Discussion
The ﬁrst fall is a milestone in the life of patients with PD, and
it is usually recalled with reasonable accuracy by patients and
relatives. In the present survey, the prevalence and frequency
of falls and the morbidity they caused were similar to those
of other reported series [5, 39]. In short, we conﬁrmed that
falls are frequent and recurrent in patients with PD and
responsible for fractures in about one-third of fallers and for
other relevant injuries in a further 25% of patients.
Using a series of statistical methods, we found that the
independent variables most associated with falls were the
Tinetti Balance score and Hoehn and Yahr staging. The
Tinetti Balance test predicted falls in our patients with 71%
sensitivity and 79% speciﬁcity, and Hoehn and Yahr staging
predicted falls with 77% sensitivity and 71% speciﬁcity.
The Tinetti test is a simple, widely used, qualitative test
comprising two subscales, one to assess clinical balance and
another to assess gait [36]. The balance subscale consists of
nine items, where lower scores indicate poor balance. The
Tinetti test is a reliable and valid clinical test to measure
balance and gait in elderly people and in patients with PD
[40].WefoundtheTinettiBalancesubscaletobeausefultool
for assessing the risk of falls in PD with even higher accuracy
than the total Tinetti test score.
In our study, most PD fallers were Hoehn and Yahr stage
III or more. Thus, the transition from stage II to III, with4 Parkinson’s Disease
Table 1: Demographic and disease characteristicsa.
All patients (n = 160) Nonfallers (n = 98) Fallers (n = 62) Testb P value
Age (y) 72.0 (9.5) 70.6 (9.6) 74.2 (8.9) 1 0.012
Male (%) 52.5 47.9 53.2 2 0.884
Age at onset (y) 63.9 (11,2) 64.2 (11,1) 63.5 (11.3) 1 0.682
Disease duration (y) 8.1 (6.4) 6.4 (5.4) 10.6 (7.0) 3 <0.001
PD subtype at onset 2 0.012
TDT (n, %) 100 (62.5) 69 (70.5) 31 (50.0)
ART (n, %) 60 (37.5) 29 (29.5) 31 (50.0)
Motor ﬂuctuations (n, %) 46 (28.8) 20 (20.4) 26 (41.9) 2 0.003
Dyskinesias (n, %) 42 (26.3) 18 (18.3) 24 (38.7) 2 0.004
Hoehn and Yahr 2.6 (1.0) 2.1(0,8) 3.2 (1.0) 1 <0.001
Hoehn and Yahr (n,% )
(I) 21 (13.1)
(II) 63 (39.4)
(III) 44 (27.5)
(IV) 23 (14.4)
(V) 9 (5.6)
(I) 18 (18.4)
(II) 52 (53.1)
(III) 21 (21,4)
(IV) 5 (5.1)
(V) 2 (2.0)
(I) 3 (4.8)
(II) 11 (17.7)
(III) 23 (37.1)
(IV) 18 (29.1)
(V) 7 (11.3)
UPDRS III 28.8 (15.6) 23.5 (13.0) 37.2 (15.8) 1 <0.001
FOG (n, %) 70 (43.8) 30 (30.6) 40 (64.5) 2 <0.001
FOG questionnaire 4.5 (5.8) 2.7 (4.6) 7.4 (6.4) 1 <0.001
Activities of daily living 73.7 (25.3) 82.1 (19.0) 60.4 (28.3) 1 <0.001
MMSE 26.8 (4.7) 27.6 (3.8) 25.7 (5.8) 3 0.038
Hypertension (n, %) 62 (38,8) 38 (38.7) 24 (38.7) 2 0.993
Diabetes (n, %) 16 (10.0) 7 (7.1) 9 (14.4) 2 0.130
Stroke (n, %) 6 (3.7) 2 (1.9) 4 (6.0) 2 0.208
Neuroimaging of CVD (n, %) 35 (21.9) 22 (22.4) 13 (20.9) 2 0.825
Symptomatic orthostasis (n, %) 58 (36.2) 33 (33.6) 25 (24.8) 2 0.416
Syncope (n, %) 1 (0,6) 0 1 (1.6) 2 0.765
Abbreviations. PD: Parkinson disease; UPDRS: Uniﬁed Parkinson’s Disease Rating Scale; FOG: freezing of gait; MMSE: minimental State Examination; TDT:
tremor-dominant subtype; ART: akinetic-rigid subtype; CVD: cerebrovascular disease.
aData are mean (SD), absolute numbers, and percentages.
bTest 1 = Mann-Whitney U test; test 2 = χ2test; test 3 = independent samples t-test.
the emergence of postural instability, plays a crucial role in
the appearance of falls and is related to increased disability
in many gait-dependent activities [41]. As expected, balance
dysfunction seems to be the main cause of falls in patients
with PD. Postural instability in PD is caused by deﬁcits in
several components of postural control, such as hypometric
preparatory adjustments, delayed reaction time, abnormal
automatic postural reactions, and abnormal axial kinesthesia
[39, 42, 43]. Postural instability occurs in the course of
PD as a consequence of disease progression. Therefore,
fallers had longer disease duration and increased disease
severity based on the UPDRS, Hoehn and Yahr and Schwab-
England activities of daily living scores, and more frequently
experienced motor ﬂuctuations and dyskinesia. For the same
reasons, fallers were treated with higher doses of levodopa
and more frequently used COMT inhibitors. These results
are in keeping with similar ﬁndings from other studies [3, 5,
17, 25].
Freezing of gait was more frequent among fallers,
although its statistical relevance was overcome by postural
instability. Freezing of gait can precipitate falls in unstable
patients [12] and could be the principal cause of falls in a
subgroup of patients with PD.
Tremor as the initial predominant motor symptom was
more frequent among nonfallers. This ﬁnding is consistent
withtheslowerclinicalprogressiontoHoehnandYahrstages
III to V found in parkinsonian patients with a tremor-
dominant clinical subtype in prospective clinicopathological
studies [44].
MMSE scores were worse in fallers. This may reﬂect the
interaction between cognitive function and gait and posture
abnormalities [45, 46], although executive function and
attention were not speciﬁcally assessed in our study. On the
other hand, cognitive decline might be an epiphenomenon
related to more advanced disease in PD fallers.
Inourseries,therewasnostatisticalsigniﬁcantdiﬀerence
in history of symptoms of orthostatic hypotension between
fallers and nonfallers, although blood pressure measure-
ments in supine and standing positions were not performed.
An interesting ﬁnding was that the risk of falls in PD
increased exponentially with age, especially from 70 years
onward. Thus, ageing seems to play an important role inParkinson’s Disease 5
Table 2: Functional tests, gait parameters, and drug treatments a.
All patients (n = 160) Nonfallers (n = 98) Fallers (n = 62) Testb P value
Tinetti
Balance 10.9 (5.7) 13.4 (3.9) 7.1 (6.0) 1 <0.001
Gait 8.6 (4,6) 10.3 (3.2) 5.8 (5.2) 1 <0.001
Total 19.5 (10.2) 23.7 (7.0) 12.9 (11.0) 1 <0.001
Timed up and go (s) 11.4 (8.0) 10.7 (7.9) 13.1 (8.1) 1 0.004
Velocity (m/s) 1.17 (0.31) 1.19 (0.30) 1.10 (0.32) 1 0.293
Step length (m) 0.77 (0.20) 0.79 (0,24) 0.69 (0.22) 1 0.093
Cadence (steps/s) 1.55 (0.70) 1.52 (0.23) 1.61 (0.41) 1 0.253
Levodopa use (n, %) 139 (86.8) 84 (85.7) 55 (88.7) 2 0.639
Levodopa dose (mg/d) 557.8 (254.1) 504.1 (208.3) 638.7 (295.8) 1 0.005
Dopamine agonist use (n, %) 98 (61.2) 58 (59.2) 40 (64.5) 2 0.511
MAOB-I use (n, %) 49 (30.6) 29 (29.5) 20 (32.2) 2 0.728
COMT-I use (n, %) 25 (15.6) 10 (10.2) 15 (24.2) 2 0.025
Amantadine use (n, %) 13 (8,1) 5 (5.1) 8 (12.9) 2 0.134
Anticholinergic use (n, %) 2 (1.2) 2 (2.0) 0
Polytherapy (n, %) 83 (51.8) 49 (50.0) 34 (54.8) 2 0.649
Benzodiazepine use (n, %) 22 (13.7) 12 (12.2) 10 (16.1) 2 0.490
Antidepressant use (n, %) 18 (11.2) 11 (11.2) 7 (11.3) 2 1.000
Neuroleptic use (n, %) 8 (5.0) 1 (1.0) 7 (11.3) 2 0.006
Cholinesterase inhibitor use
(n,% ) 7 (4.3) 0 7 (11.3) 2 0.001
Abbreviations. MAOBI: inhibitor of monoamine oxidase B; COMTI: inhibitor of catechol-O-methyl transferase.
aData are mean(SD), absolute numbers, or percentage.
bTest 1 = independent samples t-test; test 2 = χ2 test.
Table 3: Logistic regression analysis.
Bivariate analysis Multivariate analysis
Odds ratio 95% CI P value Odds ratio 95% CI P value
Age 1.04 0.99–1.08 0.025 1.04 0.95–1.14 0.381
Disease duration 1.12 1.05–1.19 <0.001 0.96 0.89–1.03 0.326
PD subtype 2.37 1.22–4.60 0.010 2.07 0.89–4.80 0.090
Motor ﬂuctuations 2.81 1.39–5.69 0.004 1.91 0.75–5.62 0.200
Dyskinesia 2.80 1.36–5.78 0.005 0.98 0.33–2.87 0.972
Hoehn and Yahr 3.06 2.04–4.60 <0.001 1.59 0.72–3.50 0.247
UPDRS 1.06 1.03–1.09 <0.001 0.98 0.94–1.04 0.658
FOG 4.42 2.24–8.72 <0.001 1.65 0.67–4.03 0.274
FOG questionnaire 1.15 1.08–1.22 <0.001 1.01 0.89–1.22 0.131
Activities of daily living∗ 0.96 0.94–0.97 <0.001 1.02 0.92–1.14 0.807
MMSE∗ 0.91 0.85–0.98 0.017 1.02 0.93–1.13 0.640
Tinetti Balance∗ 0.80 0.74–0.86 <0.001 0.84 0.74–0.97 0.017
Tinetti Gait∗ 0.80 0.73–0.87 <0.001 1.13 0.95–1.43 0.256
Tinetti total∗ 0.89 0.85–0.93 <0.001 0.93 0.87–1.01 0.690
Get-up-and-go 0.95 0.90–1.01 0.189
Levodopa dose 1.002 1.001–1.004 0.005 1.02 0.94–1.19 0.944
COMT-I use 2.80 1.17–6.74 0.021 3.41 1.06–11.37 0.052
Neuroleptic use 12.34 1.48–102.98 0.020 1.25 0.16–12.67 0.854
Cholinesterase inhibitor use 11.92 2.12–12.34 0.002 1.11 0.23–11.78 0.756
Abbreviations. PD: Parkinson disease; UPDRS: Uniﬁed Parkinson’s Disease Rating Scale; FOG: freezing of gait; MMSE: Minimental State Examination.
∗ Functional tests: higher scores means normality.6 Parkinson’s Disease
Table 4: Receiver operating characteristic analyses.
AUC Sensitivity Speciﬁcity Accuracy % Cut-oﬀ value
Tinetti Balance 0.81 0.71 0.79 0.76 11.5
Tinetti total 0.81 0.60 0.86 0.52 17.5
Hoehn and Yahr 0.78 0.77 0.71 0.74 2.5
Tinetti Gait 0.77 0.71 0.74 0.76 10.5
UPDRS III 0.76 0.77 0.70 0.72 26.5
Activities of daily living 0.74 0.73 0.66 0.69 85
Disease duration 0.70 0.71 0.70 0.70 7.5
FOG questionnaire 0.70 0.55 0.84 0.74 8.5
Levodopa dose 0.66 0.79 0.49 0.61 425
Age 0.62 0.52 0.69 0.54 76.5
MMSE 0.60 0.23 0.89 0.63 22.5
Abbreviations. AUC: area under the curve; UPDRS: Uniﬁed Parkinson’s Disease Rating Scale; FOG: freezing of Gait; MMSE: Minimental State Examination.
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Figure 1: Receiver operating characteristic curves of the Tinetti Balance score (Figure 1(a)) and Hoehn and Yahr staging (Figure 1(b)). AUC,
sensitivity, speciﬁcity, and accuracy are shown in Table 4.
advanced PD, perhaps by hastening the underlying disease
process, thus allowing neuropathological changes to spread
rapidly to neural structures related to gait and balance
control in the late stages of the disease [47]. Furthermore, in
our survey, patients who developed clinical symptoms of PD
after the age of 70 experienced falls signiﬁcantly earlier than
those with a younger onset, illustrating the combined eﬀect
of ageing and disease progression. In fact, age at onset of PD
should be taken into account when considering early falls as
a red ﬂag that may question the clinical diagnosis of PD.
A limitation of this study is the retrospective assessment
of falls. It has been suggested that elderly people tend to
forget previous falls [48]. However, the accuracy of dating
past falls may depend on how subjects are interviewed. We
managed to date falls, particularly the ﬁrst one, with the
combined information of patients, relatives, caregivers, and
clinical records. In addition, the survival curve for time to
the ﬁrst fall after the onset of PD in our analysis was similar
to that of the only long-term study of patients with PD in
which falls were prospectively assessed [5], although it was
notdesignedtoinvestigateriskfactorsoffalling.Thisimplies
that our survey, despite its cross-sectional design, does not
present important biases in the assessment of falls.
AlthoughthepredictivevalueforfallsinPDoftheTinetti
test and Hoehn and Yahr staging is limited, and other more
reﬁned tests of balance deﬁcits in PD should be developed,Parkinson’s Disease 7
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Figure 2: Kaplan-Meier curve showing that the risk of falls in-
creases exponentially with age, mainly from the age 70 onward.
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Figure 3: Kaplan-Meier curve showing that the risk of falls in-
creases with the duration of Parkinson’s disease.
the use of these simple and rapid clinical tests may help iden-
tify high-risk patients.
In elderly people without PD, exercise programs speciﬁ-
callytargetingbalancehaveproventobeparticularlyeﬀective
in preventing falls [49]. Targeted exercise improves balance
in PD [50], and cueing training can improve freezing of
gait [51]. In addition, a recent study has suggested that the
treatment with central cholinesterase inhibitors may reduce
falls in nondemented PD patients [52].
Research eﬀorts should be directed toward ﬁnding better
predictors of falls in PD— perhaps using posturography
[53] or other electrophysiological devices for testing postural
stability [54]—and toward developing therapeutic strategies
to improve balance and prevent falls in these patients.
40 30 20 10 0
1
0.8
0.6
0.4
0.2
0
>70
≤70
W
i
t
h
o
u
t
f
a
l
l
s
(
%
)
Duration of PD ( years)
Figure 4: Kaplan-Meier curve showing the eﬀect of age at onset
of Parkinson’s disease on the appearance of falls. Patients with age
at onset >70 years fall earlier than younger patients (log rank P<
0.001).
Appendix
TinettiFunctionalTest [36]
Balance Tests: Subject is seated in hard, armless chair. The
following maneuvers are tested.
(a) Sitting balance
(i) Leans or slides in chair (0)
(ii) Steady, safe (1)
(b) Arises
(i) Unable without help (0)
(ii) Able, uses arms to help (1)
(iii) Able, without using arms (2)
(c) Attempts to arise
(i) Unable without help (0)
(ii) Able, requires >1 attempt (1)
(iii) Able to rise, 1 attempt (2)
(d) Immediate standing balance (ﬁrst 5 seconds)
(i) Unsteady (swaggers, moves feet, trunk sway)
(0)
(ii) Steady but uses walker or other support (1)
(iii) Steady without walker or other support (2)
(e) Standing balance
(i) Unsteady (0)
(ii) Steady but wide stance (heels >10.16cm [4 inc]
apart and uses cane or other support (1)
(iii) Narrow stance without support (2)8 Parkinson’s Disease
(f) Nudged (subject with feet as close together as possi-
ble, examiner pushes lightly on subject’s sternum 3
times)
(i) Begins to fall (0)
(ii) Staggers, grabs, catches self (1)
(iii) Steady (2)
(g) Eyes closed (subject with feet as close together as
possible)
(i) Unsteady (0)
(ii) Steady (1)
(h) Turning 360◦
(i) Discontinuous steps (0)
(ii) Continuous (1)
(iii) Unsteady (grabs, staggers) (2)
(iv) Steady (3)
(i) Sitting down
(i) Unsafe (misjudged distance, falls into chair)
(0)
(ii) Uses arms or not a smooth motion (1)
(iii) Safe, smooth motion (2)
GaitTests:Subjectstandswithexaminer,walksdownhallway
or across room, ﬁrst at “usual pace”, then back at “rapid, but
safe pace” (using usual walking aids).
(a) Initiation of gait
(i) Any hesitancy or multiple attempts to start (0)
(ii) No hesitancy (1)
(b) Step length and height
(i) Right swing foot does not pass right stance foot
with step (0)
(ii) Passes left stance foot (1)
(iii) Left swing foot does not pass right stance foot
with step (0)
(iv) Passes right stance foot (1)
(v) Right foot does not clear ﬂoor completely with
step (0)
(vi) Right ﬂoor completely clears ﬂoor (1)
(vii) Left foot does not clear ﬂoor completely with
step (0)
(viii) Left ﬂoor completely clears ﬂoor (1)
(c) Step symmetry
(i) Right and left step lengths not equal (estimate)
(0)
(ii) Right and left steps appear equal (1)
(d) Step continuity
(i) Stopping or discontinuing between steps (0)
(ii) Steps appear continuous (1)
(e) Path (estimated in relation to ﬂoor tiles, 30.48cm [12
in] diameter; observed excursion of 1 foot over about
3m [10ft] of the course)
(i) Marked deviation (0)
(ii) Mild/moderate deviation or uses walking
aid (1)
(iii) Straight without walking aid (2)
(f) Trunk
(i) Marked sway or uses walking aid (0)
(ii) No sway but ﬂexion of knees or back or spread
arms (1)
(iii) No sway, no ﬂexion, no use of arms, and no use
of walking aid (2)
(g) Walking stance
(i) Heels apart (0)
(ii) Heels almost touching while walking (1)
Balance score .../16
Gait score .../12
Balance score + gait score .../28
Modiﬁed from: Tinetti ME. Performed-oriented assessment
of mobility problems in elderly patients. Journal of the
American Geriatrics Society 1986; 34:119–126.
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